- Home
- MGNX vs INBX Comparison
MGNX vs INBX Comparison
Compare MGNX & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- INBX
- Stock Information
- Founded
- MGNX 2000
- INBX 2010
- Country
- MGNX United States
- INBX United States
- Employees
- MGNX N/A
- INBX N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- MGNX Health Care
- INBX Health Care
- Exchange
- MGNX Nasdaq
- INBX Nasdaq
- Market Cap
- MGNX 257.3M
- INBX 222.5M
- IPO Year
- MGNX 2013
- INBX 2020
- Fundamental
- Price
- MGNX $3.24
- INBX $14.08
- Analyst Decision
- MGNX Buy
- INBX Hold
- Analyst Count
- MGNX 11
- INBX 1
- Target Price
- MGNX $8.57
- INBX N/A
- AVG Volume (30 Days)
- MGNX 770.4K
- INBX 74.9K
- Earning Date
- MGNX 11-05-2024
- INBX 11-14-2024
- Dividend Yield
- MGNX N/A
- INBX N/A
- EPS Growth
- MGNX N/A
- INBX N/A
- EPS
- MGNX N/A
- INBX 119.38
- Revenue
- MGNX $141,329,000.00
- INBX $1,568,000.00
- Revenue This Year
- MGNX $119.63
- INBX N/A
- Revenue Next Year
- MGNX N/A
- INBX N/A
- P/E Ratio
- MGNX N/A
- INBX $0.12
- Revenue Growth
- MGNX 16.68
- INBX 19.24
- 52 Week Low
- MGNX $2.95
- INBX $10.80
- 52 Week High
- MGNX $21.88
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- MGNX 37.79
- INBX 38.78
- Support Level
- MGNX $3.61
- INBX $13.64
- Resistance Level
- MGNX $5.10
- INBX $14.63
- Average True Range (ATR)
- MGNX 0.35
- INBX 1.00
- MACD
- MGNX -0.10
- INBX -0.20
- Stochastic Oscillator
- MGNX 4.62
- INBX 35.47
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.